Phaarmasia Ltd

Phaarmasia Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 09 February 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 21 February 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Phaarmasia Ltd has seen its investment rating upgraded from Sell to Hold, reflecting significant improvements across technical indicators and valuation metrics. The company’s recent financial performance, coupled with a bullish technical outlook and attractive valuation compared to peers, has prompted this reassessment by analysts as of 09 Feb 2026.

Phaarmasia Ltd has witnessed a significant re-rating in its valuation parameters, transitioning from a previously expensive profile to one now deemed attractive by market standards. This shift is underscored by a notable improvement in its price-to-earnings (P/E) and price-to-book value (P/BV) ratios relative to both historical levels and peer benchmarks within the Pharmaceuticals & Biotechnology sector.

Phaarmasia Limited, a micro-cap pharmaceutical manufacturer specialising in oral contraceptive tablets, delivered a dramatic quarterly turnaround in Q2 FY26, posting net profit of ₹1.74 crores compared to a loss of ₹0.64 crores in the same quarter last year. The 140.90% sequential revenue surge to ₹16.55 crores and return to profitability triggered a 4.99% stock rally to ₹103.63, though the shares remain 21.34% below their 52-week high of ₹131.75.

Phaarmasia Ltd, a player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 4 February 2026, reflecting a complex interplay of technical indicators, valuation metrics, financial trends, and quality assessments. Despite strong recent financial results and impressive long-term returns, concerns over weak fundamentals and expensive valuation have weighed heavily on the outlook.

Phaarmasia Ltd is rated 'Hold' by MarketsMOJO, a rating that was last updated on 18 Nov 2025. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 30 January 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Phaarmasia Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 18 Nov 2025. While the rating change occurred then, the analysis and financial metrics discussed here reflect the stock's current position as of 19 January 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Phaarmasia Ltd has reached a significant milestone by hitting a new 52-week high of Rs.131.75 today, reflecting robust momentum in the Pharmaceuticals & Biotechnology sector. This achievement underscores the stock’s sustained upward trajectory over recent weeks, outpacing sector performance and demonstrating strong investor confidence in its current valuation.

Phaarmasia Ltd has surged to a fresh 52-week high of Rs.129.2, reflecting a robust rally that has propelled the stock to outperform its sector and demonstrate sustained upward momentum over the past fortnight.

Phaarmasia Ltd has surged to a fresh 52-week high of Rs.126.7, reflecting a robust rally that has propelled the stock to outperform its sector and demonstrate sustained upward momentum over the past several trading sessions.

Phaarmasia Ltd has reached a significant milestone by hitting a new 52-week high of Rs.122.2 today, reflecting robust momentum in the Pharmaceuticals & Biotechnology sector. This achievement comes after a sustained rally, with the stock gaining 15.01% over the past eight consecutive trading sessions.

Phaarmasia Ltd has surged to a fresh 52-week high of Rs.121.85, reflecting a robust rally that has propelled the stock to outperform its sector and demonstrate sustained upward momentum over the past week.

Phaarmasia Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 18 Nov 2025. While the rating change occurred on that date, the analysis and financial metrics presented here reflect the stock's current position as of 06 January 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Phaarmasia Ltd surged to a fresh 52-week high of Rs.119.5 on 5 Jan 2026, reflecting robust upward momentum in the Pharmaceuticals & Biotechnology sector. The stock has demonstrated sustained gains over the past week, outperforming its sector peers and trading well above key moving averages.